TRIlogy-4: Ramantamig’s Triple Target Attack on Myeloma—BCMA, GPRC5D, and CD3 #EHA2026

In this video, we explore the Phase 3 TRIlogy-4 clinical trial evaluating ramantamig (JNJ-79635322), the first trispecific antibody to enter Phase 3 testing in multiple myeloma. Ramantamig is designed to simultaneously target BCMA and GPRC5D on myeloma cells while engaging CD3 on T cells, bringing the immune system directly to the cancer. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.